<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103644</url>
  </required_header>
  <id_info>
    <org_study_id>FMBSUREC/10102021/Rabie</org_study_id>
    <nct_id>NCT05103644</nct_id>
  </id_info>
  <brief_title>Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients&quot;</brief_title>
  <official_title>Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fayoum oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins, a major class of drugs for treatment of hypercholesterolemia, are widely used due to&#xD;
      a notable prevention of cardiovascular disease, and accumulating evidence proposes a&#xD;
      promising role of statins in breast cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statin has lipid independent effects include inhibition of inflammatory responses,&#xD;
      immunomodulatory actions, apoptotic and antiproliferative effects, which might contribute to&#xD;
      the suggested anti-tumoral effects of these agents. The epidemiological evidence projecting&#xD;
      statins as anticancer agents is variable, depending on the particular type of cancer in&#xD;
      question as well as the class of statin used&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>study group control group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ki-67 molecular</measure>
    <time_frame>3 month</time_frame>
    <description>antiproliferative effect Ki-67 molecular gene expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TAZ (WWTR1) TAZ expression</measure>
    <time_frame>3 months</time_frame>
    <description>cell proliferative ability via TAZ (WWTR1) TAZ expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cardiac markers</measure>
    <time_frame>3 months</time_frame>
    <description>protective effect of atorvastatin for Anthracycline induced cardiotoxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival OS</measure>
    <time_frame>time frame 6 month</time_frame>
    <description>The length of time from r the start of treatment for a disease and are still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>6 months</time_frame>
    <description>the proportion of patients who have a partial or complete response to therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>breast cancer patient received Atorvastatin 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>breast cancer patient received placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 80mg</intervention_name>
    <description>patients received statin experimental group</description>
    <arm_group_label>study</arm_group_label>
    <other_name>ATOR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>patients received placebo control group</description>
    <arm_group_label>control group</arm_group_label>
    <other_name>placebo single blind</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed breast cancer any stage confirmed by radiological and pathological or by&#xD;
             clinical evaluation undergo surgery or receiving neo/adjuvant chemotherapy treatment&#xD;
&#xD;
          2. Age above 18 years&#xD;
&#xD;
          3. HER2 negative core biopsy&#xD;
&#xD;
          4. Adequate renal function: the calculated creatinine clearance should be ≥50 mL/min&#xD;
&#xD;
          5. Patients must be accessible for treatment and follow-up&#xD;
&#xD;
          6. Performance status of Eastern Cooperative Oncology Group (ECOG) ≤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity reaction to the investigational compounds or incorporated&#xD;
             substances&#xD;
&#xD;
          2. patients who are unlikely to comply with trial requirements (eg, confusion,&#xD;
             psychological or mood disturbances ,alcoholism, cardiac arrhythmia)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Femal breast cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Hassan shaaban, MD</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raghda RS Hussein, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Beni-Suef University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reham shehab El-Nemr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fayoum University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ALshaimaa Ibrahim Rabie, Msc</last_name>
    <phone>01061263030</phone>
    <email>alshaimaa.ph@o6u.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raghda RS Hussein, PHD</last_name>
    <email>Raghda.hussien@phram.bsu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beni-Suef university hospital</name>
      <address>
        <city>Banī Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Hasssan Shaaban, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fayoum Oncology Center</name>
      <address>
        <city>Fayoum</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alshaimaa Ibrahim, Rabie</last_name>
      <email>alshaimaa.ph@o6u.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>ALshaimaa Ibrahim Rabie</investigator_full_name>
    <investigator_title>clinical pharmacist Msc, Pharm D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

